+117.2%
MPC vs MRNA
+945.0%
-827.8%
-19.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -8.1% | +13.1% | -21.2% | -7.9% |
| 7D | -10.9% | +20.6% | -31.6% | -10.7% |
| 30D | -9.4% | +27.1% | -36.6% | -9.0% |
| 3M | +26.0% | +353.4% | -327.4% | +29.1% |
| 6M | +56.5% | +446.3% | -389.7% | +59.7% |
| YTD | +144.3% | +776.2% | -631.9% | +140.0% |
| 1Y | +117.2% | +987.9% | -870.7% | +102.7% |
| All | +117.2% | +945.0% | -827.8% | +102.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling